Estrogen receptor-alpha 36 mediates mitogenic antiestrogen signaling in ER-negative breast cancer cells

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Zhang, XinTian ^a   Ding, Ling ^b   Kang, LianGuo ^a   Wang, Zhao Yi ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AFIMOXIFENE; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA 36; FULVESTRANT; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE; STAT5 PROTEIN; UNCLASSIFIED DRUG; 2 MORPHOLINO 8 PHENYLCHROMONE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; 4,17 BETA DIHYDROXY 4 ANDROSTENE 3 ONE; 4,17 BETA-DIHYDROXY-4-ANDROSTENE-3-ONE; CHROMONE DERIVATIVE; DRUG DERIVATIVE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA, HUMAN; MORPHOLINE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TESTOSTERONE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STIMULATION; CELL STRAIN MDA MB 231; CELL STRAIN MDA MB 436; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; MITOGENESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; BREAST TUMOR; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMONES; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; HYDROXYTESTOSTERONES; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MORPHOLINES; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84856024073     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030174     Document Type: Article

References (52)

1. Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, et al. (2001) Mechanisms of estrogen action. Physiol Rev 81: 1535-1565.
2. Kelly MJ, Levin ER, (2001) Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol Metab 12: 152-156.
3. Segars JH, Driggers PH, (2002) Estrogen action and cytoplasmic signaling cascades. Part I: membrane-associated signaling complexes. Trends Endocrinol Metab 13: 349-354.
4. Osborne CK, Coronado E, Allred DC, Wiebe V, DeGregorio M, (1991) Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst 83: 1477-1482.
5. Osborne CK, Wiebe VJ, McGuire WL, Ciocca DR, DeGregorio MW, (1992) Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J Clin Oncol 10: 304-310.
6. Howell A, Dodwell DJ, Anderson H, (1990) New endocrine approaches to breast cancer. Baillieres Clin Endocrinol Metab 4: 67-84.
7. Wakeling AE, Dukes M, Bowler J, (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res 51: 3867-3873.
8. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M, (2000) Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103: 843-852.
9. Fawell SE, White R, Hoare S, Sydenham M, Page M, et al. (1990) Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci U S A 87: 6883-6887.
10. Dauvois S, Danielian PS, White R, Parker MG, (1992) Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci U S A 89: 4037-4041.
11. Nicholson RI, Gee JM, Manning DL, Wakeling AE, Montano MM, et al. (1995) Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and-resistant experimental and clinical breast cancer. Ann N Y Acad Sci 761: 148-163.
12. Zhao L, O'Neill K, Brinton RD, (2006) Estrogenic agonist activity of ICI 182,780 (Faslodex) in hippocampal neurons: implications for basic science understanding of estrogen signaling and development of estrogen modulators with a dual therapeutic profile. J Pharmacol Exp Ther 319: 1124-1132.
13. Sibonga JD, Dobnig H, Harden RM, Turner RT, (1998) Effect of the high-affinity estrogen receptor ligand ICI 182,780 on the rat tibia. Endocrinology 139: 3736-3742.
14. Wu J, Liang Y, Nawaz Z, Hyder SM, (2005) Complex agonist-like properties of ICI 182,780 (Faslodex) in human breast cancer cells that predominantly express progesterone receptor-B: implications for treatment resistance. Int J Oncol 27: 1647-1659.
15. Robertson JA, Zhang Y, Ing NH, (2001) ICI 182,780 acts as a partial agonist and antagonist of estradiol effects in specific cells of the sheep uterus. J Steroid Biochem Mol Biol 77: 281-287.
16. Dudley MW, Sheeler CQ, Wang H, Khan S, (2000) Activation of the human estrogen receptor by the antiestrogens ICI 182,780 and tamoxifen in yeast genetic systems: implications for their mechanism of action. Proc Natl Acad Sci U S A 97: 3696-3701.
17. Brinton RD, (2001) Cellular and molecular mechanisms of estrogen regulation of memory function and neuroprotection against Alzheimer's disease: recent insights and remaining challenges. Learn Mem 8: 121-133.
18. McEwen B, (2002) Estrogen actions throughout the brain. Recent Prog Horm Res 57: 357-384.
19. Zhao L, O'Neill K, Diaz Brinton R, (2005) Selective estrogen receptor modulators (SERMs) for the brain: current status and remaining challenges for developing NeuroSERMs. Brain Res Brain Res Rev 49: 472-493.
20. Wong JK, Le HH, Zsarnovszky A, Belcher SM, (2003) Estrogens and ICI182,780 (Faslodex) modulate mitosis and cell death in immature cerebellar neurons via rapid activation of p44/p42 mitogen-activated protein kinase. J Neurosci 23: 4984-4995.
21. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, et al. (2005) Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem Biophys Res Commun 336: 1023-1027.
22. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, et al. (2006) A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci U S A 103: 9063-9068.
23. Zou Y, Ding L, Coleman M, Wang Z, (2009) Estrogen receptor-alpha (ER-alpha) suppresses expression of its variant ER-alpha 36. FEBS Lett 583: 1368-1374.
24. Lee LM, Cao J, Deng H, Chen P, Gatalica Z, et al. (2008) ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and-negative human breast carcinomas. Anticancer Res 28: 479-483.
25. Shi L, Dong B, Li Z, Lu Y, Ouyang T, et al. (2009) Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer. J Clin Oncol 27: 3423-3429.
26. Vranic S, Gatalica Z, Deng H, Frkovic-Grazio S, Lee LM, et al. (2011) ER-alpha36, a novel isoform of ER-alpha66, is commonly over-expressed in apocrine and adenoid cystic carcinomas of the breast. J Clin Pathol 64: 54-57.
27. Kang L, Zhang X, Xie Y, Tu Y, Wang D, et al. (2010) Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling. Mol Endocrinol 24: 709-721.
28. Lin SL, Yan LY, Zhang XT, Yuan J, Li M, et al. (2010) ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways. PLoS One 5: e9013.
29. Zhang XT, Kang LG, Ding L, Vranic S, Gatalica Z, et al. (2011) A positive feedback loop of ER-alpha36/EGFR promotes malignant growth of ER-negative breast cancer cells. Oncogene 30: 770-780.
30. Fox EM, Bernaciak TM, Wen J, Weaver AM, Shupnik MA, et al. (2008) Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells. Mol Endocrinol 22: 1781-1796.
31. Yamashita H, Iwase H, Toyama T, Fujii Y, (2003) Naturally occurring dominant-negative Stat5 suppresses transcriptional activity of estrogen receptors and induces apoptosis in T47D breast cancer cells. Oncogene 22: 1638-1652.
32. Brockman JL, Schroeder MD, Schuler LA, (2002) PRL activates the cyclin D1 promoter via the Jak2/Stat pathway. Mol Endocrinol 16: 774-784.
33. Zhang CC, Shapiro DJ, (2000) Activation of the p38 mitogen-activated protein kinase pathway by estrogen or by 4-hydroxytamoxifen is coupled to estrogen receptor-induced apoptosis. J Biol Chem 275: 479-486.
34. Mandlekar S, Yu R, Tan TH, Kong AN, (2000) Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Res 60: 5995-6000.
35. Obrero M, Yu DV, Shapiro DJ, (2002) Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death. J Biol Chem 277: 45695-45703.
36. Mandlekar S, Kong AN, (2001) Mechanisms of tamoxifen-induced apoptosis. Apoptosis 6: 469-477.
37. Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, et al. (2003) Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22: 7316-7339.
38. Kang L, Wang ZY, (2010) Breast cancer cell growth inhibition by phenethyl isothiocyanate is associated with down-regulation of oestrogen receptor-alpha36. J Cell Mol Med 14: 1485-1493.
39. Mahfoudi A, Roulet E, Dauvois S, Parker MG, Wahli W, (1995) Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc Natl Acad Sci U S A 92: 4206-4210.
40. Pearce ST, Liu H, Jordan VC, (2003) Modulation of estrogen receptor alpha function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12. J Biol Chem 278: 7630-7638.
41. Nichols M, Rientjes JM, Stewart AF, (1998) Different positioning of the ligand-binding domain helix 12 and the F domain of the estrogen receptor accounts for functional differences between agonists and antagonists. EMBO J 17: 765-773.
42. Kurebayashi J, Otsuki T, Yamamoto S, Kurosumi M, Nakata T, et al. (1998) A pure antiestrogen, ICI 182,780, stimulates the growth of tamoxifen-resistant KPL-1 human breast cancer cells in vivo but not in vitro. Oncology 55 (Suppl 1): 23-34.
43. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, et al. (1993) Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci U S A 90: 11162-11166.
44. Gu Q, Korach KS, Moss RL, (1999) Rapid action of 17beta-estradiol on kainate-induced currents in hippocampal neurons lacking intracellular estrogen receptors. Endocrinology 140: 660-666.
45. Das SK, Taylor JA, Korach KS, Paria BC, Dey SK, et al. (1997) Estrogenic responses in estrogen receptor-alpha deficient mice reveal a distinct estrogen signaling pathway. Proc Natl Acad Sci U S A 94: 12786-12791.
46. Pendaries C, Darblade B, Rochaix P, Krust A, Chambon P, et al. (2002) The AF-1 activation-function of ERalpha may be dispensable to mediate the effect of estradiol on endothelial NO production in mice. Proc Natl Acad Sci U S A 99: 2205-2210.
47. Nethrapalli IS, Singh M, Guan X, Guo Q, Lubahn DB, et al. (2001) Estradiol (E2) elicits SRC phosphorylation in the mouse neocortex: the initial event in E2 activation of the MAPK cascade? Endocrinology 142: 5145-5148.
48. Song RX, Barnes CJ, Zhang Z, Bao Y, Kumar R, et al. (2004) The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc Natl Acad Sci U S A 101: 2076-2081.
49. Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, et al. (2000) Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J 19: 5406-5417.
50. Cowell LN, Graham JD, Bouton AH, Clarke CL, O'Neill GM, (2006) Tamoxifen treatment promotes phosphorylation of the adhesion molecules, p130Cas/BCAR1, FAK and Src, via an adhesion-dependent pathway. Oncogene 25: 7597-7607.
51. Superti-Furga G, Courtneidge SA, (1995) Structure-function relationships in Src family and related protein tyrosine kinases. Bioessays 17: 321-330.
52. Zwick E, Hackel PO, Prenzel N, Ullrich A, (1999) The EGF receptor as central transducer of heterologous signalling systems. Trends Pharmacol Sci 20: 408-412.